Artemisinin-base combination compound or pharmaceutically acceptable salt thereof, pharmaceutical preparation and application

A compound and artemisinin technology, applied in the field of medicine, can solve the problems of significant toxic and side effects, and achieve the effects of good drug resistance, good anti-tumor activity, and low toxic and side effects

Pending Publication Date: 2021-09-28
GUIZHOU UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, a number of base-based anti-metabolites have been used in the field of clinical anti-tumor for many yea

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Artemisinin-base combination compound or pharmaceutically acceptable salt thereof, pharmaceutical preparation and application
  • Artemisinin-base combination compound or pharmaceutically acceptable salt thereof, pharmaceutical preparation and application
  • Artemisinin-base combination compound or pharmaceutically acceptable salt thereof, pharmaceutical preparation and application

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0066] Artemisinin - Preparation of base The main reaction was split programs are:

[0067]

[0068] Means Het Het as defined hereinbefore 1 Or Het 2 ;

[0069]

[0070] Wherein, BF 3 · Et 2 O is boron trifluoride diethyl ether, TFA is trifluoroacetic acid, Het 1 As hereinbefore defined;

[0071]

[0072] DIAD is diisopropyl azodicarboxylate, TPP is triphenylphosphine, X is as hereinbefore defined.

Example Embodiment

[0073] Example 1: 10-O- [2- (9H-9- purin-yl) - ethyl] - Preparation of dihydroartemisinin - (10S)

[0074] Step A: 10-O- (2- bromo-ethyl) - (10S) - Preparation of dihydroartemisinin

[0075]

[0076] Lower 5g (17.6mmol) dihydroartemisinin (DHA) and 1.25mL (17.6mmol) 2- bromoethanol was dissolved in 100mL purified THF (tetrahydrofuran) in a nitrogen atmosphere, an ice bath was slowly added dropwise 3.5mL (0.50g , 3.5mmol) of boron trifluoride diethyl ether (BF 3 · Et 2 O), the reaction was stirred for 6 hours. The reaction by TLC (ethyl acetate: petroleum ether = 1: 4) monitoring. After completion of the reaction, saturated NaHCO 3 Solution. The organic layer was collected delamination, the aqueous layer (25mL × 2) separated and extracted with ethyl acetate, and the combined organic layers. The organic layer was washed with 20mL saturated saline solution, then dried over anhydrous Na 2 SO 4 Sulfate, and the solvent was removed by distillation under reduced pressure a crude produc...

Example Embodiment

[0082] Example 2: 10-O- [2- (6- Amino-purin--9H-9- yl) - ethyl] - Preparation of dihydroartemisinin - (10S)

[0083] Prepared according to Example 1, the raw material instead of an adenine The title compound was prepared in Example 1 starting material 9H- purin embodiment;

[0084] LC-MS (m / z): 446.2 [M + H] +

[0085] 1 H NMR (CDCL 3 , Δ (ppm)): δ8.34 (s, 1H, Pur-H), 7.88 (s, 1H, Pur-H), 6.26 (s, 2H, -NH 2 ), 5.01 (s, 1H, H-12), 4.77 (d, J = 3.5Hz, 1H, H-10), 4.59-4.46 (m, 1H, -OCH 2 C H 2 -), 4.41-4.24 (m, 2H, -OC H 2 C H 2 -), 3.76 (ddd, J = 10.2,6.5,3.6Hz, 1H, -OC H 2 CH 2 -), 2.63-2.57 (m, 1H, H-9), 2.38-2.30 (m, 1H, H-4), 1.42 (s, 3H, H-14), 0.94 (d, J = 6.2Hz, 3H , H-16), 0.80 (d, J = 7.4Hz, 3H, H-15).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an artemisinin-base combination compound or a pharmaceutically acceptable salt thereof. The invention also discloses a medicinal preparation containing the artemisinin-base combination compound or the pharmaceutically acceptable salt thereof, and application of the artemisinin-base combination compound or the pharmaceutically acceptable salt thereof in preparation of medicines for treating and/or preventing primary or multidrug resistant leukemia, breast cancer, prostate cancer, liver cancer and lung cancer. Based on the characteristics of artemisinin and base compounds, a series of artemisinin-base combination compounds are designed and synthesized; according to the compound, the structure of artemisinin is modified and optimized, so that the compound not only has relatively good anti-tumor activity, but also is small in toxic and side effects and good in drug resistance; and the combination compound or the pharmaceutically acceptable salt thereof can be widely used for preparing medicinal preparations and can be applied to treatment and/or prevention of various cancers.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to an artemisinin-base complex or a pharmaceutically acceptable salt thereof and a pharmaceutical preparation containing the artemisinin-base complex or a pharmaceutically acceptable salt thereof, and The invention relates to the application of the artemisinin-base complex or a pharmaceutically acceptable salt thereof in the preparation of medicines for treating and / or preventing various cancers. Background technique [0002] In 2020, there will be an estimated 19.3 million new cancer cases and nearly 100 million cancer patient deaths worldwide. The global cancer burden is projected to reach 28.4 million by 2040, a 47% increase from 2020. Malignant tumors are a serious threat to human health, and their mechanism of occurrence is complex, and the acquired drug resistance in their drug treatment significantly reduces the success rate of drug treatment. The multi-target drug strategy ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D519/00C07D493/20A61P35/00A61P35/02A61K31/52A61K31/513
CPCC07D519/00C07D493/20A61P35/00A61P35/02
Inventor 钟杭李冰清丁洁
Owner GUIZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products